Zealand Pharma A/S (ZLDPF)
40.00
0.00 (0.00%)
USD |
OTCM |
Oct 05, 16:00
Zealand Pharma Enterprise Value : 644.22M for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 644.22M |
| October 02, 2026 | 644.22M |
| October 01, 2026 | 511.58M |
| September 30, 2026 | 899.75M |
| September 29, 2026 | 783.16M |
| September 28, 2026 | 783.16M |
| September 25, 2026 | 783.16M |
| September 24, 2026 | 783.16M |
| September 23, 2026 | 861.00M |
| September 22, 2026 | 861.00M |
| September 21, 2026 | 853.67M |
| September 18, 2026 | 853.67M |
| September 17, 2026 | 853.67M |
| September 16, 2026 | 853.67M |
| September 15, 2026 | 853.67M |
| September 14, 2026 | 853.67M |
| September 11, 2026 | 1.089B |
| September 10, 2026 | 1.089B |
| September 09, 2026 | 1.089B |
| September 08, 2026 | 1.089B |
| September 04, 2026 | 1.178B |
| September 03, 2026 | 1.178B |
| September 02, 2026 | 1.154B |
| September 01, 2026 | 1.154B |
| August 31, 2026 | 1.104B |
| Date | Value |
|---|---|
| August 28, 2026 | 1.292B |
| August 27, 2026 | 1.292B |
| August 26, 2026 | 1.468B |
| August 25, 2026 | 1.468B |
| August 24, 2026 | 1.219B |
| August 21, 2026 | 1.378B |
| August 20, 2026 | 1.342B |
| August 19, 2026 | 1.342B |
| August 18, 2026 | 1.277B |
| August 17, 2026 | 1.277B |
| August 14, 2026 | 1.530B |
| August 13, 2026 | 1.530B |
| August 12, 2026 | 1.468B |
| August 11, 2026 | 1.468B |
| August 10, 2026 | 1.377B |
| August 07, 2026 | 1.377B |
| August 06, 2026 | 1.168B |
| August 05, 2026 | 1.168B |
| August 04, 2026 | 1.168B |
| August 03, 2026 | 1.168B |
| July 31, 2026 | 1.100B |
| July 30, 2026 | 1.100B |
| July 29, 2026 | 1.100B |
| July 28, 2026 | 1.100B |
| July 27, 2026 | 994.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Genmab A/S | 26.74B |
| Ascendis Pharma A/S | 14.56B |
| Bavarian Nordic A/S | 2.184B |
| Evaxion AS | 19.38M |
| ACADIA Pharmaceuticals, Inc. | 2.579B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 609.41M |
| Revenue (Quarterly) | 698.72M |
| Total Expenses (Quarterly) | 89.30M |
| EPS Diluted (Quarterly) | 8.610 |
| Gross Profit Margin (Quarterly) | 99.76% |
| Profit Margin (Quarterly) | 87.22% |
| Earnings Yield | 15.00% |
| Operating Earnings Yield | 12.90% |
| Normalized Earnings Yield | 15.12 |